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Previously, we have reported a lipid-based Trp2 peptide 
vaccine for immunotherapy against melanoma. The sup-
pressive immune microenvironment in the tumor is a major 
hurdle for an effective vaccine therapy. We hypothesized 
that curcumin (CUR) would remodel the tumor micro-
environment to improve the vaccine activity. Curcumin–
polyethylene glycol conjugate (CUR–PEG), an amphiphilic 
CUR-based micelle, was delivered intravenously (i.v.) to 
the tumor. Indeed, in the B16F10 tumor–bearing mice, 
the combination of CUR–PEG and vaccine treatment 
resulted in a synergistic antitumor effect (P < 0.001) com-
pared to individual treatments. In the immune organs, the 
combination therapy significantly boosted in vivo cyto-
toxic T-lymphocyte response (41.0 ± 5.0% specific killing) 
and interferon-γ (IFN-γ) production (sevenfold increase). 
In the tumor microenvironment, the combination therapy 
led to significantly downregulated levels of immunosup-
pressive factors, such as decreased numbers of myeloid-
derived suppressor cells and regulatory T cells (Treg) cells 
and declined levels of interleukin-6 and chemokine ligand 
2—in correlation with increased levels of  proinflammatory 
cytokines, including tumor necrosis factor-α and IFN-γ as 
well as an elevation in the CD8+ T-cell population. The 
results indicated a distinct M2 to M1 phenotype switch 
in the treated tumors. Combining CUR–PEG and vaccine 
also dramatically downregulated the signal transducer 
and activator of transcription 3 pathway (76% reduction). 
Thus, we conclude that CUR–PEG is an effective agent to 
improve immunotherapy for advanced melanoma.
Received 24 June 2015; accepted 26 August 2015; advance online  
publication 13 October 2015. doi:10.1038/mt.2015.165
INTRODUCTION
Cancer immunotherapy is based on certain approaches intended to 
generate immune responses against malignant cells.1 Melanomas, 
some of the most immunogenic tumors, are often the targets of these 
approaches, among which, vaccination strategies play important 
roles in the immunotherapeutic interventions by specifically boost-
ing both the innate and adaptive immune responses.2 However, as 
the tumor escalates to a late stage, the local tumor microenvironment 
becomes dominantly immunosuppressive, which avoid immune 
recognition and elimination.3,4 This results in the compromised suc-
cesses of therapeutic vaccines. Breaking down the innate and adap-
tive systems barriers and reversing the tumor microenvironment as 
well as the whole periphery of the system in order to achieve a maxi-
mal antitumor efficacy and longer survival rate remains a challenge 
for us. Our nano-based vaccine platform, containing both tumor-
associated antigen Trp2 and CpG ODN (a Toll-like receptor 9 ago-
nist) adjuvant,5 exhibited a potent antitumor ability against murine 
melanoma in the early stages. Although our vaccine still could stim-
ulate a strong cytotoxic T-cell response once the tumor progressed 
to a late stage, it was not able to inhibit tumor growth effectively. This 
is most likely due to the suppressive tumor microenvironment pres-
ent in late-stage tumors. Myeloid-derived suppressor cells (MDSCs) 
are such kinds of immune-suppressive cells in the immune organs 
and tumor tissue.6,7 It has been shown that elevated MDSCs sup-
press the immune response, promoting tumor growth through 
impairing dendritic cell antigen presentation functions and CD8+ 
T-cell killing.8 In addition, signal transducer and activator of tran-
scription 3 (STAT3) signaling pathway also plays an important role 
in facilitating tumor growth.9,10 The constitutively activated STAT3 
in the tumor is believed to block the secretion of proinflammatory 
mediators (such as interferon-γ (IFN-γ), interleukin-12 (IL-12), etc.) 
and to increase that of immunosuppressive factors (such as MDSC, 
vascular endothelial growth factor, IL-10, etc.).11,12 The reduction 
of MDSCs and blockade of STAT3 pathway have been indicated as 
strategies for the purpose of enhancing the effectiveness of cancer 
immunotherapy. To remodel the microenvironment, it is also neces-
sary to get help from a drug that could play pivotal roles not only in 
killing tumor cells but also in dealing with the immune environment 
such as reducing MDSCs13 or downregulation of STAT3.14,15
Curcumin (CUR), a component of turmeric and one of the 
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a chemodrug.16,17 As a well-known JAK-STAT3 pathway inhibi-
tor,14,15,18 CUR inhibits MDSCs in the spleen and tumor tissue 
in breast cancer models19 and 3LL Lewis lung cancer models.20 
However, its lipophilic nature and relatively low solubility in aque-
ous solutions create a major challenge in clinical applications as a 
potent anticancer agent. In an effort to circumvent these obsta-
cles, numerous strategies have been tried to enhance anticancer 
efficacy, including development of delivery systems such as lipo-
somes,14,21 poly(lactic-co-glycolic acid) nanoparticles (NPs),22 and 
other polymeric micelles.23,24 In our present work, we synthesized 
an intracellular-labile amphiphilic CUR-based micelle as our drug 
delivery system.25,26 Previous results showed that this novel micelle 
system exhibited enhanced anticancer activity in several cell lines 
both in vitro and in vivo.14,21–24 If combined with a cancer thera-
peutic vaccine, curcumin–polyethylene glycol conjugate (CUR–
PEG) would probably boost the tumor immune environment,18,19 
effectively fighting against aggressively advanced melanoma.
Based on the above researches, intracellular-labile CUR–PEG 
micelles may synergize with our lipid/calcium/phosphate nanopar-
ticles (LCP NPs) based vaccine for the treatment of advanced mela-
noma. The combination of CUR–PEG and Trp2 vaccine treatment 
may break down the barriers of cancer immunotherapy, achieving 
enhanced cytotoxic T-cell killing, inhibition of tumor-promoting sig-
naling pathways, and tumor microenvironment modulation. In our 
present works, the two modalities were rationally combined for the 
following studies (Figure 1c). The anticancer efficacy of the com-
bined therapy was compared with the two individual treatments and 
a control group. Subsequently, in vivo cytotoxic T-lymphocyte (CTL) 
response, IFN-γ production, key signaling pathways, and changes in 
the local tumor microenvironment were also studied to verify our 
hypothesis.
RESULTS
Characterization of the CUR–PEG micelle
First, the CUR–PEG was synthesized and dissolved in sterile 5% 
glucose in order to form nanoscaled micelles. The mean diam-
eters and zeta potentials of the micelle NPs were 45.3 ± 5.4 nm and 
−6.5 ± 2.1 mV, respectively. For further confirmation of the mor-
phologies and sizes of the particles, transmission electron micros-
copy pictures were taken showing that the mean sizes of micelles 
were about 45 nm (Supplementary Figure S1a–c). In vitro, CUR–
PEG could enter into B16F10 cells in 1 hour, exhibiting higher 
cellular uptake than free CUR (Supplementary Figure S1d,e).
Biodistribution of CUR–PEG and CUR
CUR–PEG is stable in the blood circulation but is quickly hydro-
lyzed to release CUR in the presence of glutathione or esterase 
when it enters into the tumor cytosol.25 Thus, the prodrug CUR–
PEG exhibited the same property as free CUR in the intracellular 
compartment. To compare the biodistribution of CUR–PEG with 
that of free CUR, two groups of mice were intravenously (i.v.) 
injected with CUR–PEG and intraperitoneally (i.p.) injected with 
free CUR, respectively. After 1, 4, and 24 hours of injection, the 
concentrations of CUR in different organs were determined and 
the biodistribution of CUR in the mice is shown in Figure 1a. In 
the free CUR group, most of the drugs accumulated in the kidneys 
and blood after 1 hour and were quickly cleared from the blood 
circulation and body. After 24 hours, there was no detectable CUR 
in the tumor tissue and blood. On the other hand, the i.v. injected 
CUR–PEG group showed a much higher concentration in liver, 
kidney, and tumor after 1 and 4 hours. After 24 hours, there was 
still a modest amount of CUR in the tumor tissue even though the 
liver and spleen were still the major accumulation sites. Therefore, 
the PEGylated CUR micelles achieved significantly higher levels 
in the tumor tissue compared to the free CUR. The improved 
CUR bioavailability enhanced passive tumor accumulation most 
likely due to the enhanced permeability and retention effect of 
the leaky tumor vasculature.27–29 However, the drug concentra-
tion in the tumor tissue, estimated to be 0.8 µg/ml at 24 hours, 
was still not high enough to significantly inhibit tumor growth 
in this advanced melanoma model (compared to its IC50 in vitro; 
Supplementary Figure S1f). Thus, we suspected that any signifi-
cant antitumor activity of the CUR–PEG must be the result of its 
action in the tumor microenvironment.
Combined therapy with CUR–PEG and vaccine-
improved antitumor response against B16F10 tumor
CUR is a mild antitumor agent. In order to maximize its efficacy 
against an aggressive melanoma, a peptide cancer vaccine for-
mulated in LCP NP was used as the synergistic agent. A peptide 
derived from the tumor-associated antigen Trp2 was phosphory-
lated and encapsulated in the NPs. The vaccine containing calcium 
phosphate, phosphopeptide, and CpG adjuvant in the central core 
and a wrapping asymmetric lipid membrane was first developed 
in our lab.30 The vaccine showed a good therapeutic activity for 
the treatment of preexisting melanoma. Even in the immune-
suppressive microenvironment, with compromised antitumor 
activity, the vaccinated mice could exhibit moderate specific 
T-cell response. As shown in Figure 1b, both the Trp2 vaccine 
group and CUR–PEG-only group showed a slight tumor inhibi-
tion activity (P < 0.05). On the contrary, the combination group 
significantly inhibited tumor growth (P < 0.001) compared to the 
control group. There was no decrease in body weight observed in 
any of the four treatment groups (data not shown), indicating that 
neither vaccine nor CUR–PEG caused toxicity. This result veri-
fied our hypothesis that the chemodrug combined with the Trp2 
vaccine indeed exhibited superior antitumor efficacy even in this 
relatively late-stage tumor–bearing mouse model when a suppres-
sive tumor microenvironment existed.5
CUR–PEG enhanced in vivo CTL response and IFN-γ 
production elicited by the vaccine
To elucidate why the vaccine could significantly improve the 
therapeutic effect of CUR–PEG in the advanced melanoma tumor 
model, an in vivo CTL assay was performed for the purpose of 
adaptive immune response evaluation. The antigen-specific CTL 
response plays a pivotal role in stopping the growth of the tumor 
by directly killing tumor cells through the excretion of perforin, 
granzyme, IFN-γ, and TNF-α.31 As shown in Figure 2a,b, the 
control group and CUR–PEG-treated group were not able to gen-
erate any detectable Trp2 peptide–specific CTL response. Mice 
that were immunized with the Trp2 vaccine exhibited a moder-
ate Trp2-specific cytotoxic T-cell killing. Mice treated with both 
CUR–PEG and the vaccine elicited the strongest CTL response 
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Figure 1 Drug biodistribution determination and tumor growth inhibition experiment. (a) CUR–PEG and CUR biodistribution in tumor-bear-
ing mice. CUR was dissolved in dimethyl sulfoxide and administered through i.p. injection. An equivalent amount of CUR–PEG was i.v. injected 
in the B16F10 tumor–bearing mice. Treated mice were sacrificed and different organs were collected at 1, 4, and 24 hours. (b) Antitumor effi-
cacy of the different treatments against B16F10 melanoma. About 2 × 105 B16F10 cells were inoculated in C57BL/6 mice on day 0. Trp2 vaccine 
was given on day 12 and 16 (blue arrows). CUR–PEG was i.v. injected every other day for a total of five doses (black arrows). Tumor volumes 
were measured every 2–3 days. Data show mean ± SD, n = 10. *P < 0.05, ***P < 0.001. (c) The schematic representation of the combination 
therapy. APC, antigen-presenting cells; CCL2, chemokine ligand 2; CTL, cytotoxic T lymphocyte; CUR–PEG + Vac, curcumin–polyethylene glycol 
conjugate–treated and vaccinated group; DC, dendritic cell; IFN, interferon; IL, interleukin; LCP NPs, lipid/calcium/phosphate nanoparticles; 
MDSC, myeloid-derived suppressor cell; NP, nanoparticle; s.c., subcutaneous; STAT3, signal transducer and activator of transcription 3; TNF, 
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in comparison with the other groups. The data indicated a syner-
gized adaptive immunity through the CD8+ T-cytotoxic pathway.
IFN-γ is produced predominantly by cytotoxic T cells, medi-
ating tumor rejection once adaptive immune response develops. 
So, an IFN-γ production study may further illustrate the syner-
gized mechanism. IFN-γ production by lymphocytes was ana-
lyzed using a BD ELISPOT assay system. As shown in Figure 2c,d, 
consistent with the result of the in vivo CTL assay, splenic cells 
extracted from both the control group and CUR–PEG group 
could barely generate IFN-γ. Failure to produce IFN-γ confirmed 
that these treatments could not induce Trp2-specific immune 
response. On the other hand, the group treated with the Trp2 vac-
cine obtained modest IFN-γ production. The combination group 
exhibited a dramatically increased amount of IFN-γ.
Changes of tumor-infiltrating immune cells and 
cytokine levels in tumor microenvironment
To further elucidate why the combination strategy could efficiently 
inhibit tumor growth, we also checked the changes of the related 
immune regulatory subsets and cytokines in the tumor microen-
vironment, in which, cancer cells, tumor-infiltrating lymphocytes, 
neovasculature, fibroblasts, and secreted cytokines all partake in a 
complicated interplay network.32 Results were quantified by flow 
cytometry and were also shown by immunostaining of tumor 
sections. MDSCs were checked as the first regulatory subset. As 
shown in Figure 3a, the percentages of MDSC in the CUR–PEG-
only group and combination group were much lower than those 
for both the vaccine and control groups. Since MDSCs can estab-
lish immune tolerance by induction of regulatory T cell (Treg) 
development, the blockage of MDSC may lead to inhibition of 
Treg. We therefore detected the percentage of Treg in tumor tis-
sues (Figure 3a). Consistent with the trends of MDSCs, the CUR–
PEG drug–treated group and combination group exhibited fewer 
Treg cells than the vaccine and control groups. The depletion of 
MDSC and Treg cells may facilitate effector T cells,3 and there-
fore the CD8+ T cells were also detected. As shown in Figure 3a, 
the vaccine group and combination group both induced a sig-
nificant increase in CD8+ T cells compared to the control and 
CUR–PEG-only groups. Immunostaining further confirmed the 
flow cytometry results (Figure 3b). Our results indicated that the 
single-treatment groups could only partially reverse the immu-
nosuppressive microenvironment. For example, the vaccine-only 
Figure 2 In vivo cytotoxic T-lymphocyte (CTL) response and ELISPOT assay. (a,b) In vivo CTL response after different treatments. Targeted lym-
phocytes from naive mice were pulsed with ovalbumin (OVA) or Trp2 peptides and then stained with 0.5 or 5 µmol/l carboxyfluorescein succinimidyl 
ester (CFSE), respectively. The mix of both pulsed cells were injected back into the vaccinated mice though the tail vein. Sixteen hours after injection, 
splenocytes were separated again and analyzed with flow cytometry. The specific lysis activity of CTL was calculated using the equation mentioned in 
the Materials and Methods section. n = 3. A representative graph from each treatment is shown. (c,d) Interferon-γ (IFN-γ) production from the treated 
mice. Spleens were collected from which single-cell suspension was prepared 7 days after the second vaccination. The splenocytes were cocultured 
with either OVA or Trp2 peptide at 37 °C for 18 hours. The production of IFN-γ was calculated with a BD ELISPOT assay set. One of the representative 
results is shown in c. n = 3. *P < 0.05; **P < 0.01, ***P < 0.001. All data show mean ± SD. CUR–PEG + Vac, curcumin–polyethylene glycol conjugate–
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group could increase the number of CD8+ T cells, but there was 
no decrease in MDSCs or Treg cells. The CUR–PEG-treated 
group could both decrease MDSC and Treg cell population, but 
due to the lack of vaccine, the amount of CD8+T cells in the drug-
only group was still the same as that of the control group. Only 
the combination group could decrease both MDSCs and Treg 
cells while increasing the CD8+ T cells, indicating an effective 
reversion of the suppressed microenvironment.
We then monitored the cytokine levels in the local tumor tissue 
in order to see whether or not the combination group could reverse 
the suppressed microenvironment via cytokine levels (Figure 3c). 
As we know, IL-6 is a potent pleiotropic inflammatory cytokine 
Figure 3 Changes of tumor-infiltrating immune cells and cytokine levels in tumor microenvironment. The B16F10 murine–bearing mice 
were divided into four groups and treated with phosphate-buffered saline, vaccine, CUR–PEG, or CUR–PEG/vaccine, respectively. At the end of 
treatment, mice were euthanized and tumor tissues were collected for (a) flow cytometry assay and (b) immunostaining evaluation: the first 
panel shows the MDSCs (orange), the second panel shows the Treg cells (orange), and the third panel shows the CD8+ T cells (green). *P < 0.05, 
**P < 0.01, ***P < 0.001. Data show mean ± SEM. Bar = 200 µm. The statistical analyses were calculated by comparison with the control group if 
not specifically mentioned. (c) Cytokine level detection using quantitative real-time PCR. n = 4, *P < 0.05, **P < 0.01. The statistical analyses were 
calculated by comparison with the control group if not specifically mentioned. All data show mean ± SD. CCL2, chemokine ligand 2; CUR–PEG + 
Vac, curcumin–polyethylene glycol conjugate–treated and vaccinated group; DAPI, 4′,6-diamidino-2-phenylindole; IFN, interferon; IL, interleukin; 
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that is considered a key growth-promoting and antiapoptotic fac-
tor.33,34 Chemokine ligand 2 (CCL2) is a small cytokine, which is 
critical for immunosuppression to promote cancer metastasis. 
Meanwhile, IFN-γ and tumor necrosis factor-α (TNF-α) are the 
cytokines secreted by cytotoxic T cells that facilitate T-cell kill-
ing and fight against tumor progression.31,35 Compared with the 
control group, cytokines in the vaccine group neither increased 
nor decreased substantially (P > 0.05), indicating that the vaccine 
was not potent enough to inhibit the indicators in the suppressive 
microenvironment even though it could partially induce cytotoxic 
T cells. In the CUR–PEG group, CCL2 and IL-6 decreased substan-
tially, and TNF-α and IFN-γ also slightly decreased although with-
out significant differences (P > 0.05). In the combination group, 
CCL2 and IL-6 were significantly decreased, even when compared 
to the CUR–PEG treatment group. However, TNF-α and IFN-γ 
were dramatically increased, indicating a M2 to M1 phonotype 
switch36–38 to an immune-stimulating microenvironment.39,40 This 
would consequently facilitate tumor antigen presentation and acti-
vate recruitment of lymphocytes to act as scavengers and result in a 
robust cytotoxic T-cell-mediated tumor–specific killing.
STAT3 expression level was downregulated by the 
combination treatment
What was the underlying mechanism that changed the immuno-
suppressive microenvironment to an immune-responsive tumor 
microenvironment in the combination therapy? Recent studies have 
identified that inhibiting STAT3 signaling pathway plays a pivotal 
role in cancer immunotherapy. STAT3 can be activated by IL-6–
mediating signaling and by various other cytokines.34,41 Considering 
that the levels of IL-6 in the tumor tissue decreased in the CUR–PEG 
group and the combination group, p-STAT3 expression levels were 
detected using western blotting analysis. First, B16F10 cells were 
treated with different concentrations of CUR–PEG and free CUR in 
vitro. Results showed that CUR–PEG could inhibit the STAT3 path-
way like free CUR itself (Figure 4a), indicating that CUR–PEG is 
a prodrug for CUR. The inhibition was concentration dependent. 
Levels of p-STAT3 and STAT3 were then analyzed in vivo. In Figure 
4b–d, the p-STAT3 and STAT3 levels were not downregulated in 
either the vaccine group or the CUR–PEG-alone group when com-
pared with the control group. In the combination group, however, 
the p-STAT3 level was dramatically downregulated, even the STAT3 
expression itself was slightly lower than other groups.
Changes of the tumor vessel and tumor-associated 
fibroblast
Tumor-associated fibroblasts (TAFs) and angiogenesis impede the 
infiltration of CTLs to the tumor tissues. The effect of the vaccine 
and drug on TAFs was investigated by staining for α-smooth mus-
cle actin (α-SMA), a marker of TAFs, and CD31, a marker for the 
vasculature. The density and mean florescence were detected by 
fluorescence microscopy. Three microscopic fields were randomly 
selected for analysis. As shown in Figure 5a, the density of α-SMA 
and CD31 in the vaccine-only and drug-only groups was lower 
than that of the control group. The combination group exhibited 
the lowest density of α-SMA and CD31, which is consistent with 
previous reports of CUR’s antiangiogenic activity.14,42
Combination therapy–enhanced tumor apoptosis
Finally, the apoptotic assay was also performed. The apoptotic 
tumor cells act as both the adaptive immune response initiator 
Figure 4 STAT3 levels after various treatments using western blotting assay. (a) In vitro p-STAT3 level changes after treatment with free CUR and an 
equivalent amount of CUR–PEG. (b) p-STAT3 expression levels in tumor tissues at the end of the treatments. Three repeated results were quantitatively 
analyzed using Image J. (c) p-STAT3 expression levels in tumor tissues. (d) STAT3 expression levels. *P < 0.05, ***P < 0.001. Data show mean ± SEM. 
CUR–PEG + Vac, curcumin–polyethylene glycol conjugate–treated and vaccinated group; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; 
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and the reactor. As shown in Figure 5b, only a trace amount of 
terminal deoxynucleotidyl transferase dUTP nick end label-
ing (TUNEL)-positive cells were observed in the control group, 
whereas a small amount of TUNEL-positive nuclei (green fluores-
cent dots) were observed in vaccine-only group. The CUR–PEG-
alone group showed a moderate amount of apoptotic cells. But 
in the combination group, an extensive amount of apoptotic cells 
were observed. Once again, the above results clearly demonstrate 
that the combination treatment showed superior antitumor activ-
ity compared to either of the single-treatment groups.
Toxicity evaluation for the different treatments and 
blood chemistry analysis
The results of the toxicological evaluation demonstrated that there 
were not any noticeable morphological changes in the heart, liver, 
spleen, lungs, and kidneys for all of the four treatment groups. 
The serum biochemical value analysis demonstrated that the drug 
treatment group had no liver (aspartate aminotransferase and 
alanine aminotransferase) or kidney (creatinine and blood urea 
nitrogen) toxicity caused by tumor progression (Supplementary 
Figure S2a,b).
Figure 5 Tumor microenvironment changes after various treatments. The B16F10 murine–bearing mice were divided into four groups and treated 
with either phosphate-buffered saline, vaccine, CUR–PEG, or CUR–PEG/vaccine. At the end of treatment, mice were euthanized and tumor tissues 
were harvested for: (a) CD31 and TAF staining: upper panels were stained with CD31, lower panels were stained with α-SMA. (b) TUNEL assay. Trace 
amount of apoptosis were found in the untreated group (the first panel). Bar = 200 µm. A small amount of TUNEL-positive nuclei (green fluorescent 
dots) were found in the vaccine-only group (the second panel). A moderate amount of apoptotic cells were observed when treated with CUR–PEG 
alone (the third panel). Extensive apoptotic cells were found in the combination group (the fourth panel). N = 3, **P < 0.01, ***P < 0.001. Data show 
mean ±SEM. CUR–PEG + Vac, curcumin–polyethylene glycol conjugate–treated and vaccinated group; DAPI, 4',6-diamidino-2-phenylindole; α-SMA, 
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DISCUSSION
The success of cancer vaccination is strongly hampered by 
immune suppression in the immune organs and tumor micro-
environment, especially when tumors have developed to later 
stages. In the study presented here, we combined a therapeutic 
vaccine and nano-based CUR–PEG for the treatment of B16F10 
melanoma and demonstrated that the combination therapy sig-
nificantly retarded tumor growth compared to the Trp2 vaccine 
or CUR–PEG alone.
In the immune organs, why only the combination treatment 
group could generate the strongest adaptive immune response, 
achieving the best antitumor efficacy compared to other groups? 
As MDSCs impair the T-cell function, strongly contributing 
to immune suppression, MDSC content in the spleen was ana-
lyzed. We found that CUR–PEG alone could significantly reduce 
MDSC numbers in the spleen of B16F10 tumor–bearing mice 
(Supplementary Figure S3), which was probably because CUR 
directly interfered with MDSC proliferation.13 MDSC is a popula-
tion of early myeloid cells that are expanded in various disease 
states, including cancers, and are capable of suppressing the 
immune response.4,43 They are more abundant in tumor-bearing 
mice than in healthy mice. Blocking T-cell activities is one of 
the main MDSC functions. MDSC impairs the efficacy of can-
cer vaccines by directly effecting dendritic cell antigen presenta-
tion and T-cell activation.32 Therefore, in the combination group, 
the reduced MDSCs caused by CUR–PEG treatment sensitized 
the CTL response when immune cells encountered with tumor 
 antigens presented by the vaccine and restored the immune- 
stimulating environment in the immune organs. In the combina-
tion treatment group, CUR–PEG played a critical role in enhancing 
the CD8+ T-cytotoxic killing and facilitated IFN-γ production, 
which resulted in a strong adaptive immune response.16,19,40 The 
more effector T cells that proliferate and circulate in the body, the 
more they can infiltrate the tumor tissues for tumor cell killing.
In the tumor microenvironment, STAT3 played a central role 
in crosstalk between cancer and immune cells.41 Activated STAT3 
not only stimulates proteins that are critical for tumor proliferation 
and survival, including cyclin D1, BCL-X, MYC, and survivin,44,45 
but also acts as an important molecule that mediates immune sup-
pression in local tumor tissues. The constitutively activated STAT3 
in tumor tissue upregulates the expression of tumor-derived fac-
tors, including IL-6 and IL-10,46 which are both STAT3 activating 
and immunosuppressive. These factors, in turn, promote STAT3 
signaling in Treg cells, MDSCs, and tolerogenic dendritic cells in 
the tumor microenvironment, which subsequently produce more 
downstream mediators such as Foxp, IL-6, IL-10, and vascular 
endothelial growth factor,47,48 creating an efficient “feedforward” 
mechanism41 to guarantee prolonged activation of STAT3 both in 
tumor cells and in immune cells. Inhibiting STAT3 activity should 
block the feedforward link as well as promote the expression of 
several proinflammatory cytokines and chemokines. Therefore, 
inhibiting the STAT3 pathway in tumor cells helped reverse the 
suppressed tumor microenvironment13,18,43,46,49 and can result in 
enhanced antitumor effect. In our case, the vaccine by itself could 
not downregulate STAT3 because of the immunosuppressive envi-
ronment in the late-stage tumor model. In the drug-only treat-
ment group, CUR–PEG decreased the levels of IL-6 and CCL2 in 
the local tumor tissue but could not increase the proinflamma-
tory cytokines such as IFN-γ and TNF-α, due to the insufficient 
CD8+ T-cell infiltration. So, it was not able to effectively inhibit 
the STAT3 pathway in vivo. Meanwhile, in the combination group, 
the more CD8+ T cells were generated and infiltrated to the tumor 
tissue, the more proinflammatory mediators (IFN-γ, IL-2, and 
TNF-α) were produced. Within the decreased level of immuno-
suppressive factors as well as the elevated level of proinflamma-
tory cytokines, the STAT3 pathway can be effectively abrogated. 
The downregulated STAT3, in turn, resulted in further activation 
of tumor antigen–specific CD8+ T cells in vivo, subsequently lead-
ing to a potent antitumor activity.
From all of the above analyses, we know that mice treated with 
the Trp2 vaccine can induce effective tumor-specific cytotoxic 
T cells even in a late-stage tumor model and that these cells can 
infiltrate into the tumor microenvironment. When the tumor 
microenvironment was immunosuppressive, cytotoxic T-cell–
mediated killing was largely abrogated. With the help of CUR–PEG 
micelles, the combination therapy could block STAT3 activation 
in the local tumor tissue by downregulating the immunosup-
pressive factors, including IL-6, CCL2, MDSCs, and Treg cells, 
which can in turn facilitate CD8+ T-cell infiltration. Additionally, 
CUR–PEG could also downregulate the MDSCs in the immune 
organs such as the spleen, which could augment the vaccine activ-
ity by producing more cytotoxic T cells. This would subsequently 
enhance the infiltrating cytotoxic T-cell numbers in a feedforward 
manner. CUR–PEG could also directly kill tumor cells through an 
apoptotic pathway, facilitating tumor antigen presentation. Lastly, 
CUR–PEG micelles accumulated in the tumor tissue could reduce 
angiogenesis, creating an immune-responsive microenviron-
ment. So, with the help of the vaccine, CUR–PEG was capable of 
lowering the antigen threshold, enhancing antigen presentation, 
and increasing T-cell accumulation within the tumor, creating 
an immune-responsive tumor microenvironment. With such a 
dynamic interaction, the combination therapy achieved an effec-
tive antitumor performance.
In conclusion, CUR–PEG micelles improved therapeutic effi-
cacy of a Trp2–LCP vaccine by reducing the MDSCs, Treg cells, 
IL-6, CCL2, and significantly reducing the STAT3 pathway as 
well as increasing the production of CTL and IFN-γ together with 
an improved cytotoxic T-cell response. Most importantly, this 
approach achieved a dramatically enhanced antitumor effect for 
the combination therapy for the late-stage melanoma, without 
causing any detectable side effects. The current study documents 
the superior value of CUR–PEG as a useful anticancer formula-
tion of CUR and its activity to augment the activity of a cancer 
vaccine.
MATERIALS AND METHODS
Reagents. Dioleoylphosphatydic acid (DOPA) and 1,2-dioleoyl-3-tri-
methylammonium-propane chloride salt (DOTAP) were purchased 
from Avanti Polar Lipids (Alabaster, AL). 1,2-Distearoryl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethyleneglycol-2000)] ammo-
nium salt (DSPE–PEG) and DSPE-PEG-NHS were purchased from 
NOF (Tokyo, Japan). Cholesterol was purchased from Sigma-Aldrich 
(St. Louis, MO). DSPE–PEG–mannose was synthesized according to 
the previously established protocol in our lab. Major histocompatibility 
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complex class I molecule-H-2Kb restricted peptides, purity 98%, oval-
bumin (OVA) (SIINFEKL, MW 1773), Trp2 (SVYDFFVWL, MW1175), 
and phosphoserine-modified Trp2 peptide (pSpSSSVYDFFVWL, 
MW1626) were synthesized by Peptide 2.0 (Chantilly, VA). CpG ODN 
1826 (5′-TCCATGACGTTCCTGACGTT-3′) was ordered from Sigma-
Aldrich. CUR was purchased from Santa Cruz (Dallas, TA). PEG methyl 
ether acrylate, 3-mercaptopropionic acid, and 4-dimethylaminopyridine 
were purchased from Sigma-Aldrich. All other chemicals were purchased 
from Sigma-Aldrich if not specifically mentioned.
Cell line, mice, and antibodies. Murine B16F10 melanoma cell line, which 
is syngeneic with C57BL/6 mice, was purchased from American Type 
Culture Collection (ATCC) and cultured in Dulbecco’s Modified Eagle’s 
medium, supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 
and 100 µg/ml streptomycin (Invitrogen, Carlsbad, CA). Six- to eight-week 
old female C57BL/6 mice were obtained from Charles River (Bethesda, 
MD). Animals were raised in the Center for Experimental Animals (an 
AAALAC accredited experimental animal facility) in the University of 
North Carolina (UNC) at Chapel Hill. All animal handling procedures 
were approved by the UNC at Chapel Hill’s Institutional Animal Care and 
Use Committee.
Primary antibodies used for western blot analysis and immunostaining 
included anti-α-SMA, glyceraldehyde 3-phosphate dehydrogenase, 
anti-CD31 polyclonal antibody (Abcam, Cambridge, MA), anti- 
p-STAT3 monoclonal antibody, and anti-STAT3 antibody (Cell Signaling, 
Cambridge, MA). Fluorescent primary antibodies including fluorescein 
isothiocyanate (FITC)-conjugated anti-mouse CD8α, FITC-conjugated 
anti-mouse CD4, PE-conjugated anti-mouse FOXP3, FITC-conjugated 
anti-mouse CD11b, and PE-conjugated anti-mouse Gr were obtained from 
BD Biosciences (San Jose, CA). Secondary antibodies used for western 
blot analysis included bovine anti-rabbit IgG–horseradish peroxidase and 
rabbit anti-mouse IgG–horseradish peroxidase purchased from Santa 
Cruz. Secondary antibody used for immunofluorescence staining Alexa 
Fluor 647 conjugated anti-rabbit was purchased from Abcam. Analysis 
was performed on a FACSCalibur flow cytometer and analyzed using Cell 
Quest software (BD Biosciences).
Synthesis of CUR–PEG and the formation characterization of micelles. 
CUR–PEG was synthesized as previously reported.25 In brief, PEG methyl 
ether acrylate, 3-mercaptopropionic acid, and trace amount of trimeth-
ylamine were mixed in anhydrous tetrahydrofuran. After mixing, these 
components were stirred for 24 hours at room temperature. After PEG 
oligomer precipitation, it was mixed with N,N′-dicyclohexylcarbodiimide, 
CUR, and 4-dimethylaminopyridine in anhydrous tetrahydrofuran con-
taining a trace amount of trimethylamine. Twenty-four hours after stir-
ring, the solution was filtered to remove dicyclohexylurea byproducts. The 
filtrate was then precipitated again with excess amount of anhydrous ether 
followed by further repeated purification steps. The purified final product 
was directly dissolved in sterile 5% glucose and injected into the C57BL/6 
mice by tail vein injection. The morphology of CUR–PEG micelles was 
observed by transmission electron microscopy (JEOL 100CX II TEM; 
Tokyo, Japan). The mean diameters and zeta potentials of the micelles 
were measured by dynamic light scattering, Malvern Zetasizer Nano ZS 
machine (Malvern, Worcestershire, UK).
Preparation of LCP-based peptide vaccine NP. The LCP–Trp2 vaccine 
NP was prepared in a water-in-oil microemulsion method as previously 
described.30 In brief, 600 µl of Na2HPO4 (12.5 mmol/l, pH 9.0) and 200 
µl of DOPA (20 mmol/l) were dispersed in 20 ml of a Cyclohexane/Igepal 
CO-520 (70:30, v/v) reverse oil solution for the formation of a well-dis-
persed phosphate phase. At the same time, 600 µl of CaCl2 (2.5 mol/l) 
containing both phospho-Trp2 peptide and CpG ODN was dispersed in 
another 20 ml reverse oil solution to obtain the calcium phase. After sepa-
rately stirring for 20 minutes, the two oil phases were immediately mixed 
together and stirred for another 30 minutes at room temperature. Then, 
40 ml of ethanol was added in order to precipitate the calcium phosphate 
cores. Calcium phosphate cores were subsequently collected by centrifu-
gation (8,582 rpm × 15–20 minutes) and washed twice with ethanol. The 
pellets were dissolved again in chloroform. For final particle preparation, 
the cores were mixed with 100 µl of DOTAP, 100 µl of cholesterol, 10 µl 
of DSPE–PEG-2000, and 10 µl of DSPE–PEG–mannose. After chloroform 
evaporation, the LCP-based vaccine was rehydrated in 100 µl of 5% glucose 
solution.
Biodistribution assay. Forty milligrams of CUR–PEG was i.v. injected into 
the tail vein of the mice. Equivalent amount of free CUR in dimethyl sulf-
oxide was i.p. injected into the mice due to its hydrophobic property. After 
1, 4, and 24 hours, mice were euthanized and the heart, liver, spleen, lungs, 
kidneys, and tumor tissues were collected. CUR was extracted by incu-
bating 100 mg of tissue in 1 ml methanol overnight. The concentrations of 
extracted CUR in different organs and the plasma were determined using 
fluorescence spectroscopy. The excitation wavelength was set at 485 nm, 
while the emission wavelength was set at 575 nm.
Tumor growth inhibition study. On day 0, 6- to 8-week-old female 
C57BL/6 mice were subcutaneously inoculated with 2 × 105 B16F10 cells 
on their lower flank. For late vaccination studies, the LCP NP vaccine 
in 5% glucose was subcutaneously injected into the contralateral side of 
the lower flank on days 12 and 16, respectively. For tumor growth inhibi-
tion studies, tumor-bearing mice were i.v. administrated with 40 mg/kg of 
CUR–PEG every other day for a total five injections once tumor volume 
reached 150 mm3. For combination therapy, mice received both the vac-
cine and repeated injections of CUR–PEG. Tumor sizes were measured 
every other day using digital calipers (Thermo Fisher Scientific, Pittsburgh, 
PA) and tumor volume was calculated using the equation: volume = 0.5 × 
length × width2. All mice were euthanized on day 23.
CTL assay (in vivo).  Seven days after the second vaccination, a CTL 
response assay was performed following the published method with slight 
modifications.5 Briefly, lymphocytes from naive C57BL/6 mice were sepa-
rated from the spleens. The single lymphocytes were immediately pulsed 
with either 10 µmol/l of control peptide (OVA) or tumor-associated 
antigen peptide (Trp2) in complete RPMI 1640 medium at 37 °C for 1.5 
hours. Both kinds of peptide-pulsed lymphocytes were then stained with 
2 µmol/l of PKH-26 strictly according to the manufacturer’s manual. OVA 
peptide–pulsed and Trp2 peptide–pulsed cells were then labeled with 
0.5 and 5 µmol/l of carboxyfluorescein succinimidyl ester (CFSE), respec-
tively. Incubating for 15 minutes, equal numbers of CFSElow cells (OVA 
control peptide pulsed) and CFSEhigh cells (Trp2 peptide pulsed) were 
mixed together and i.v. injected into the four groups of treated mice. 
After 16–18 hours, splenocytes were collected again from the vaccinated 
or control mice and subjected to flow cytometry analysis. The numbers 
of CFSElow cells and CFSEhigh cells were calculated and the in vivo Trp2-
specific lysis percentage was enumerated according to the equation below.











ELISPOT assay for IFN-γ production restimulation of spleen cells for vac-
cinated or untreated mice was performed as described previously.30 In 
brief, 7 days after the second vaccination, spleens were harvested and sepa-
rated into single-cell suspensions in a sterile condition. Following the BD 
enzyme-linked immunosorbent spot (ELISPOT) assay instructions, cells 
were seeded at 2 × 105 per well in a capture antibody coated 96-well plate. 
The single-cell suspensions were then cocultured with either 5 µmol/l of 
OVA or Trp2 peptide at 37 °C for 18 hours. At the due time, cells were 
removed by several wash steps. The production of IFN-γ was measured by 
detection antibody addition followed by enzyme conjugate magnification. 
Red dots signals were developed with a BD ELISPOT substrate set and 
calculated manually.
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Flow cytometry assay. Tumor-infiltrating and splenocyte immune lym-
phocytes were quantitatively analyzed by flow cytometry. In brief, tissues 
were harvested and digested with collagenase A and DNAase at 37 °C for 
40–50 minutes. After red blood cell lysis, cells were dispersed with 1 ml 
of phosphate-buffered saline. For intracellular cytokine staining, the cells 
from the tissues were penetrated with penetration buffer (BD, Franklin 
Lakes, NJ) following the manufacturer’s instructions. Different immune 
lymphocytes (5 × 106/ml) were stained with the fluorescein-conjugated 
antibodies mentioned in the previous section.
Quantitative real-time PCR assay. Total RNA was extracted from the 
B16F10 tumor tissues using an RNeasy kit (Qiagen, Valencia, CA). cDNA 
was reverse-transcribed using the First-Strand Synthesis System for real-
time PCR. One hundred nanograms of cDNA was amplified with the 
Taqman Universal Probes Supermix system (Bio-Rad, Hercules, CA). All 
the mouse-specific primers for real-time PCR reactions are listed in Table 1. 
Mouse β-actin was used as the endogenous control. Reactions were con-
ducted using the 7500 Real-Time PCR System and the data were analyzed 
with Image J.
Immunofluorescence staining. After the deparaffinizing step, antigen 
retrieval, and permeabilization, tissue sections were blocked in 1% bovine 
serum albumin at room temperature for 1 hour. Primary antibodies con-
jugated with fluorophores (BD) were incubated overnight at 4 °C and the 
nuclei were counterstained with 4',6-diamidino-2-phenylindole containing 
mounting medium (Vector Laboratories, Burlingame, CA). All antibod-
ies were diluted after optimization. Images were taken using fluorescence 
microscopy (Nikon, Tokyo, Japan). Three randomly selected microscopic 
fields were quantitatively analyzed using Image J software.
Western blot analysis. Tumor tissues from four different groups were 
harvested and the total proteins were extracted using radioimmunopre-
cipitation assay lysis buffer (Sigma). After homogenization, the total pro-
tein concentrations were determined using a BCA protein assay system 
(Thermo, Rockford, IL) according to the manufacturer’s instruction. For 
the gel running step, the same amount of proteins were diluted in the sam-
ple-loading buffer and heated at 95 °C for 5 minutes. After separation by 
NuPAGE Bis-Tris Gels (Invitrogen, Grand Island, NY), proteins were trans-
ferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA) by 
electrophoresis. Then the protein-loaded membranes were blocked by 5% 
nonfat dry milk (Santa Cruz) for 1 hour at room temperature and incubated 
with primary antibodies including p-STAT3, STAT3, and glyceraldehyde 
3-phosphate dehydrogenase (Cell Signaling) overnight at 4 °C. On the sec-
ond day, the membranes were incubated in horseradish peroxidase–con-
jugated secondary antibodies for 1 hour at room temperature. The Pierce 
ECL Western Blotting Substrate kit (Thermo) was used to detect the protein 
bands. The relative amounts of proteins were quantified using Image J.
TUNEL assay. TUNEL assays were performed using a DeadEnd 
Fluorometric TUNEL System (Promega, Madison, WI) for the detec-
tion of apoptotic tumor cells in the paraffin-embedded tumor tissues. 
Cells that were stained with FITC (green) fluorescence were defined as 
TUNEL-positive cells. Slides were coverslipped with Vectashield mount-
ing media with 4',6-diamidino-2-phenylindole (Vector Laboratories). 
TUNEL-positive cells were monitored using fluorescence microscopy 
(Nikon). Three randomly selected microscopic fields were quantitatively 
analyzed using Image J.
H&E morphology evaluation and blood chemistry analysis. The untreated 
mice, vaccinated mice, mice that were i.v. injected with CUR–PEG every 
other day for a total five doses, and the vaccine/CUR–PEG-cotreated 
mice were all subjected to a toxicity assay. At the end of the treatments, 
blood was collected from the different treatment groups and centrifuged 
at 4,000 rpm for 5 minutes in order to obtain the serum. Creatinine, blood 
urea nitrogen, serum aspartate aminotransferase, and alanine amino-
transferase were assayed as indicators of renal and liver function. Organs 
including the heart, liver, spleen, lungs, and kidneys were collected and 
fixed for hematoxylin and eosin (H&E) staining by UNC histology facility 
to evaluate the organ-specific toxicity.
Statistical analysis. A two-tailed Student’s t-test or a one-way analysis of 
variance were performed when comparing two groups or larger than two 
groups, respectively. Statistical analysis was performed using Prism 5.0 
Software. Differences were considered to be statistically significant if the 
P value was less than 0.05.
SUPPLEMENTARY MATERIAL
Figure S1. Characterizations of CUR–PEG micelles and B16F10 cell 
uptake.
Figure S2. H&E morphology evaluation and serum biochemical value 
analysis.
Figure S3. Changes of spleen MDSC after various treatments.
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